Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients

Author: Kontoghiorghes, George J

Source: Expert Opinion on Drug Safety, Volume 7, Number 6, November 2008 , pp. 645-646(2)

Publisher: Informa Healthcare

Buy & download fulltext article:


Price: $99.00 plus tax (Refund Policy)


There are major concerns regarding the toxicity, efficacy and costs of deferasirox in transfused iron loaded patients. Marketing policies resulted in its indiscriminate use and have overtaken safety issues. Renal, hepatic and pancytopenia fatal episodes have been reported. However, despite these fatalities it would appear that there is no regular monitoring of such toxicities or of effects such as the accumulation of toxic metals. The safety of some patients can also be compromised by the low efficacy of deferasirox in the removal of excess iron, especially from the heart, which in the long term can also result in an overall increase in morbidity and mortality. Safer, less costly and more effective treatments are available by using deferoxamine, deferiprone and their combination.

Document Type: Research Article

DOI: http://dx.doi.org/10.1517/14740330802137479

Publication date: November 1, 2008

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page